• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical applications of hallucinogens: A review.致幻剂的临床应用:综述
Exp Clin Psychopharmacol. 2016 Aug;24(4):229-68. doi: 10.1037/pha0000084.
2
Positive psychology in the investigation of psychedelics and entactogens: A critical review.积极心理学在迷幻剂和致幻剂研究中的应用:批判性评价。
Neuropharmacology. 2018 Nov;142:179-199. doi: 10.1016/j.neuropharm.2018.06.034. Epub 2018 Jun 30.
3
Psychedelics.迷幻剂。
Curr Biol. 2022 Jan 24;32(2):R63-R67. doi: 10.1016/j.cub.2021.12.009.
4
Therapeutic mechanisms of psychedelics and entactogens.迷幻剂和快感增强剂的治疗机制。
Neuropsychopharmacology. 2024 Jan;49(1):104-118. doi: 10.1038/s41386-023-01666-5. Epub 2023 Jul 24.
5
Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.梦境与迷幻剂:神经现象学比较与治疗意义。
Curr Neuropharmacol. 2017;15(7):1032-1042. doi: 10.2174/1573413713666170619092629.
6
Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.血清素能致幻剂和谷氨酰胺能致分离剂的光谱特征。
Neuroimage. 2019 Oct 15;200:281-291. doi: 10.1016/j.neuroimage.2019.06.053. Epub 2019 Jun 24.
7
Hallucinogens.致幻剂
Pharmacol Ther. 2004 Feb;101(2):131-81. doi: 10.1016/j.pharmthera.2003.11.002.
8
Ketamine, the First Associative Anesthetic? Some Considerations on Classifying Psychedelics, Entactogens, and Dissociatives.氯胺酮,第一种关联性麻醉剂?关于对致幻剂、触觉增强剂和解离性药物进行分类的一些思考。
Am J Psychiatry. 2024 Sep 1;181(9):784-786. doi: 10.1176/appi.ajp.20240644.
9
Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?高峰体验与余辉现象:致幻剂的治疗效果在何时以及如何取决于迷幻体验?
J Psychopharmacol. 2015 Mar;29(3):241-53. doi: 10.1177/0269881114568040. Epub 2015 Feb 9.
10
Classic hallucinogens in the treatment of addictions.经典致幻剂在成瘾治疗中的应用。
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:250-8. doi: 10.1016/j.pnpbp.2015.03.002. Epub 2015 Mar 14.

引用本文的文献

1
An international Delphi consensus for reporting of setting in psychedelic clinical trials.关于迷幻剂临床试验中环境报告的国际德尔菲共识。
Nat Med. 2025 Jun 3. doi: 10.1038/s41591-025-03685-9.
2
Population-based estimates of different dosage types of psychedelic use across socio-demographic groups in Germany.基于德国不同社会人口群体的迷幻剂使用不同剂量类型的人群估计。
Sci Rep. 2025 May 29;15(1):18952. doi: 10.1038/s41598-025-03873-0.
3
A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.一项关于临终时心理痛苦的迷幻剂干预措施差异的范围综述方案。
PLoS One. 2025 May 6;20(5):e0318343. doi: 10.1371/journal.pone.0318343. eCollection 2025.
4
A landscape analysis of psychedelic retreat organizations advertising online.对在线宣传的迷幻静修组织的景观分析。
PLoS One. 2025 May 2;20(5):e0321648. doi: 10.1371/journal.pone.0321648. eCollection 2025.
5
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?探索新型治疗策略:迷幻视角能否为阿尔茨海默病合并症提供有前景的解决方案?
Dialogues Clin Neurosci. 2025 Dec;27(1):1-12. doi: 10.1080/19585969.2025.2480566. Epub 2025 Mar 19.
6
Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.审视研究迷幻剂辅助心理治疗以治疗照顾者困扰的理论依据。
Psychedelic Med (New Rochelle). 2023 Jun 14;1(2):87-97. doi: 10.1089/psymed.2022.0011. eCollection 2023 Jun.
7
Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights.探索迷幻药在治疗头痛疾病中的潜力:临床考量与探索性见解
Curr Pain Headache Rep. 2025 Jan 16;29(1):28. doi: 10.1007/s11916-024-01321-8.
8
The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.非致幻性5-羟色胺2A受体(5-HT2A)药物在治疗物质使用障碍中的潜力:临床文献的叙述性综述
Expert Opin Pharmacother. 2025 Feb;26(2):133-146. doi: 10.1080/14656566.2024.2446623. Epub 2024 Dec 26.
9
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.美国医疗保健专业人员对赛洛西宾和 MDMA 作为新型疗法的知识、态度和担忧。
Sci Rep. 2024 Nov 14;14(1):28022. doi: 10.1038/s41598-024-78736-1.
10
Continuous flow synthesis of ,-dimethyltryptamine (DMT) analogues with therapeutic potential.具有治疗潜力的α,β-二甲基色胺(DMT)类似物的连续流动合成。
RSC Med Chem. 2024 Oct 7;16(1):367-72. doi: 10.1039/d4md00562g.

本文引用的文献

1
Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependence.伊博格碱作为药物依赖药物治疗的药物研发
Ann N Y Acad Sci. 1998 May;844(1):274-292. doi: 10.1111/j.1749-6632.1998.tb08242.x.
2
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.裸盖菇素联合心理支持治疗难治性抑郁症:一项开放标签可行性研究。
Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7. Epub 2016 May 17.
3
A call to reprioritise metrics to evaluate illicit drug policy.呼吁重新调整评估非法药物政策的指标优先级。
Lancet. 2016 Apr 2;387(10026):1371. doi: 10.1016/S0140-6736(16)30074-5.
4
Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.吸入高剂量鼠尾草叶大麻素A在人体中的药代动力学和激素效应的时间进程。
J Psychopharmacol. 2016 Apr;30(4):323-9. doi: 10.1177/0269881116629125. Epub 2016 Feb 15.
5
Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.纳曲酮而非酮色林可拮抗鼠尾草酚对人体的主观、心血管及神经内分泌效应。
Int J Neuropsychopharmacol. 2016 Jul 5;19(7). doi: 10.1093/ijnp/pyw016. Print 2016 Jul.
6
Psychedelics.迷幻剂
Pharmacol Rev. 2016 Apr;68(2):264-355. doi: 10.1124/pr.115.011478.
7
Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities.探索阿亚瓦斯卡的治疗潜力:急性摄入可增强与正念相关的能力。
Psychopharmacology (Berl). 2016 Mar;233(5):823-9. doi: 10.1007/s00213-015-4162-0. Epub 2015 Nov 27.
8
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey.丛集性头痛中的吲哚胺类致幻剂:丛集性头痛克星药物使用调查结果
J Psychoactive Drugs. 2015 Nov-Dec;47(5):372-81. doi: 10.1080/02791072.2015.1107664. Epub 2015 Nov 23.
9
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.一项评估右美沙芬/奎尼丁治疗痴呆患者假性延髓情绪的安全性、耐受性和有效性的开放标签研究:PRISM II结果。
CNS Spectr. 2016 Dec;21(6):450-459. doi: 10.1017/S1092852915000620. Epub 2015 Oct 16.
10
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.在裸盖菇素实验环节中对修订后的神秘体验问卷的验证。
J Psychopharmacol. 2015 Nov;29(11):1182-90. doi: 10.1177/0269881115609019. Epub 2015 Oct 6.

致幻剂的临床应用:综述

Clinical applications of hallucinogens: A review.

作者信息

Garcia-Romeu Albert, Kersgaard Brennan, Addy Peter H

机构信息

Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.

Department of Medical Informatics, Department of Veterans Affairs.

出版信息

Exp Clin Psychopharmacol. 2016 Aug;24(4):229-68. doi: 10.1037/pha0000084.

DOI:10.1037/pha0000084
PMID:27454674
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5001686/
Abstract

Hallucinogens fall into several different classes, as broadly defined by pharmacological mechanism of action, and chemical structure. These include psychedelics, entactogens, dissociatives, and other atypical hallucinogens. Although these classes do not share a common primary mechanism of action, they do exhibit important similarities in their ability to occasion temporary but profound alterations of consciousness, involving acute changes in somatic, perceptual, cognitive, and affective processes. Such effects likely contribute to their recreational use. However, a growing body of evidence indicates that these drugs may have therapeutic applications beyond their potential for abuse. This review will present data on several classes of hallucinogens with a particular focus on psychedelics, entactogens, and dissociatives, for which clinical utility has been most extensively documented. Information on each class is presented in turn, tracing relevant historical insights, highlighting similarities and differences between the classes from the molecular to the behavioral level, and presenting the most up-to-date information on clinically oriented research with these substances, with important ramifications for their potential therapeutic value. (PsycINFO Database Record

摘要

致幻剂可分为几个不同的类别,这是根据其药理学作用机制和化学结构进行的广义定义。这些类别包括迷幻剂、触觉致幻剂、分离性致幻剂和其他非典型致幻剂。尽管这些类别没有共同的主要作用机制,但它们在引发意识的暂时但深刻改变的能力方面确实表现出重要的相似之处,这种改变涉及躯体、感知、认知和情感过程的急性变化。这些效应可能促成了它们的娱乐性使用。然而,越来越多的证据表明,这些药物除了有被滥用的可能性外,可能还有治疗用途。本综述将呈现几类致幻剂的数据,特别关注迷幻剂、触觉致幻剂和分离性致幻剂,其临床效用已有最广泛的文献记载。依次介绍每一类别的信息,追溯相关的历史见解,从分子水平到行为水平突出各类别之间的异同,并呈现关于这些物质的临床导向研究的最新信息,这对它们潜在的治疗价值具有重要影响。(PsycINFO数据库记录)